^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    varlilumab (CDX 1127) (T-cell stimulant, CD27 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma

    Published date:
    08/15/2022
    Excerpt:
    Increased tumor PD-L1 and intratumoral T cell infiltration were observed in ovarian cancer patients, with increases of ≥5% associated with better progression-free survival…. Varlilumab and nivolumab were well tolerated, without significant toxicity beyond that expected for each agent alone.
    DOI:
    10.1073/pnas.2206824119